Association between IL28B polymorphisms and first-phase viral load decrease in chronic hepatitis C virus-infected patients treated with peginterferon alfa-2b/ribavirin.

doi:10.1016/j.ijantimicag.2011.08.010

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Association between IL28B polymorphisms and first-phase viral load decrease in chronic hepatitis C virus-infected patients treated with peginterferon alfa-2b/ribavirin.

International journal of antimicrobial agents - 1 Dec 2011

Arends Joop E, Fransen Justin H, Hoepelman Andy I M, van Baarle Debbie

Abstract excerpt

Host polymorphisms in the IL28B region have recently been associated with outcome of treatment for hepatitis C virus (HCV) infection. This study clearly shows an association between first-phase viral load decrease and the IL28B rs12979860 polymorphism in chronic HCV-infected patients. Furthermore, a higher treatment efficiency factor (ɛ) was found in those HCV-infected patients with a CC genotype compared with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis C, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Interferons

Share to Interleukins

Share to Polyethylene Glycols

Share to Ribavirin

Share to Viral Load

Source

Open in PubMed

Identifiers

PMID: 21974859
DOI: 10.1016/j.ijantimicag.2011.08.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association between IL28B polymorphisms and first-phase viral load decrease in chronic hepatitis C virus-infected patients treated with peginterferon alfa-2b/ribavirin.PMID 21974859Read ↗

IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.Semantic proximity Read ↗

Host genomics and HCV treatment response.Semantic proximity Read ↗

IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.Semantic proximity Read ↗

Association of Interleukin 28B Polymorphism with Clearance of Hepatitis C Virus: A Mini Review.Semantic proximity Read ↗

IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.Semantic proximity Read ↗

IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection.Semantic proximity Read ↗

The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype.Semantic proximity Read ↗

Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis.Semantic proximity Read ↗

Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms?Semantic proximity Read ↗

IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection.Semantic proximity Read ↗

IL28B single nucleotide polymorphisms in the treatment of hepatitis C.Semantic proximity Read ↗

Novel findings for the development of drug therapy for various liver diseases: Genetic variation in IL-28B is associated with response to the therapy for chronic hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.